Long Noncoding RNA Plasmacytoma Variant Translocation 1 Is Increased in Multiple Myeloma and Correlates With Lower Induction Response

Pei Li, MD¹, Xiyao Han, MD², Yinghua Xie, MM², and Yihan Liu, MD²

Abstract
Objective: This study aimed to investigate the correlation of long noncoding RNA plasmacytoma variant translocation 1 with clinical features and prognosis in patients with multiple myeloma. Methods: The bone marrow samples were collected from 128 patients with de novo symptomatic multiple myeloma (before initial treatment) and 30 healthy donors (on the enrollment). Long noncoding RNA plasmacytoma variant translocation 1 expression in bone marrow-derived plasma cells was detected by reverse transcription quantitative polymerase chain reaction. In patients with multiple myeloma, their demographics and clinical features before treatment were collected; induction treatment response (complete response and overall response rate) and survival profiles (progression-free survival and overall survival) were assessed. Results: Expression of long noncoding RNA plasmacytoma variant translocation 1 was increased in patients with multiple myeloma compared to healthy donors. Receiver-operating characteristic curve showed that long noncoding RNA plasmacytoma variant translocation 1 distinguished patients with multiple myeloma from healthy donors with an area under the curve of 0.884 (95% confidence interval: 0.829-0.940). In patients with multiple myeloma, high expression of long noncoding RNA plasmacytoma variant translocation 1 correlated with elevated β-2 microglobulin, increased International Staging System stage, and raised Del (17p), but it did not correlate with other biochemical indexes or chromosomal abnormalities. Furthermore, long noncoding RNA plasmacytoma variant translocation 1 high expression patients presented with decreased complete response and overall response rate compared to long noncoding RNA plasmacytoma variant translocation 1 low expression patients, and high expression of long noncoding RNA plasmacytoma variant translocation 1 predicted unfavorable progression-free survival as well overall survival in patients with multiple myeloma. Conclusion: Long noncoding RNA plasmacytoma variant translocation 1 might be a potential biomarker for the supervision of disease progression and prognosis in patients with multiple myeloma.

Keywords
long noncoding RNA plasmacytoma variant translocation 1, multiple myeloma, clinical features, treatment response, survival profiles

Abbreviations
ALB, albumin; AML, acute myelocytic leukemia; APL, acute promyelocytic leukemia; ASCT, autologous stem cell transplantation; AUC, area under curve; BM, bone marrow; cDNA, complementary DNA; CR, complete response; DS, Durie-Salmon; Hb, hemoglobin; Ig, immunoglobulin; ISS, International Staging System; LDH, lactate dehydrogenase; lncRNAs, long noncoding RNAs; lnc-PVT1, lncRNA plasmacytoma variant translocation 1; miRNA, microRNA; MM, multiple myeloma; ORR, overall response

¹ Department of Hematology, Huashan Hospital, Fudan University, Shanghai, China
² Department of Hematology, Shanghai Fifth People’s Hospital, Fudan University, Shanghai, China

Corresponding Author:
Pei Li, Department of Hematology, Huashan Hospital, Fudan University, 12 Middle Urumuqi Road, Shanghai 200040, China.
Email: drlipei@hotmail.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Introduction

Multiple myeloma (MM), a B-cell neoplasm, arises from an abnormal expanded plasma cell clone. It is a common hematologic disorder, which is characterized by back pain coupled with hematological abnormalities (elevated erythrocyte sedimentation rates, low platelet counts, or more rarely low total white cell counts), hypercalcemia, renal failure, anemia, and bone lesions. For current treatments, high-dose chemotherapy with autologous stem cell transplantation (ASCT) is considered as the first-line therapy for newly diagnosed patients with MM to improve survival. Whereas for patients with MM who are not suitable for ASCT, proteasome inhibitors and immunomodulation are frequently utilized. Although the multiple treatments have been greatly improved, MM remains as a large challenge featured by a classically relapsing course. Taken together, it is necessary to explore convincing biomarkers for early diagnosis and prognosis improvement of MM.

Long noncoding RNAs (lncRNAs) are transcripts typically longer than 200 nucleotides, which are crucial for regulating gene expression at posttranscriptional level to affect multiple cellular activities such as cell growth, cell cycle, and cell migration. Accumulating evidences show that various lncRNAs are vital in the development and progression of cancers, including hematologic malignancies. As one of the most common cancer-related lncRNAs, lncRNA plasmacytoma variant translocation 1 (lnc-PVT1) is located on chromosome 8q24 that is a location shared by the proto-oncogene c-Myc (an oncogenic transcription factor relating to the development of leukemia and lymphoma). Meanwhile, lnc-PVT1 is reported to not only sponge anticarcinogenic miR-203a to promote cell proliferation and repress cell apoptosis in MM but also interact with c-Myc to increase cells in G0/G1 phase and activate cell proliferation in lymphoma. Besides, previous studies disclose that lnc-PVT1 overexpression correlates with worse clinical features and poor prognosis in patients with acute myelocytic leukemia (AML). Hence, lnc-PVT1 might present with a high potential for clinical application in hematologic malignancies.

Although the underlying mechanism of lnc-PVT1 in hematologic malignances and its oncogenic role in several hematologic patients have been clarified, the clinical implication of lnc-PVT1 in patients with MM is still unclear. In our preliminary research, we discovered that lnc-PVT1 expression was higher in patients with MM, and it correlated with advanced clinical features and worse prognosis of patients with MM. Based on above mentioned, a hypothesis was proposed that lnc-PVT1 might also accelerate progression and relate to worse prognosis in patients with MM. Herein, the focus of this study was to investigate the correlation of lnc-PVT1 with clinical features and prognosis in patients with MM.

Materials and Methods

Participants

During the period between January 2016 and June 2019, 128 patients with de novo MM were consecutively enrolled from our hospital. All patients were newly confirmed as de novo MM according to 2014 International Myeloma Working Group updated criteria for the diagnosis of MM, aged 18 to 80 years old; without other hematological malignancies, solid tumors, or serious infection; no history of chemotherapy, radiotherapy, or stem cell transplantation, and not pregnant or lactating women. While the smoldering (asymptomatic) MM, relapsed MM, secondary MM, or patients with mixed MM were excluded from this study. Besides, 30 healthy individuals who underwent bone marrow (BM) donation in our hospital during the same period were recruited as healthy donors, and their health conditions were confirmed when examining the eligibilities for BM transplantation. Meanwhile, 42 patients with relapsed/refractory (R/R) MM treated in our hospital were also enrolled in the study, and all of them were aged 18 to 80 years old without other hematological malignancies. The ethical approval for this study was acquired from the Ethics Committee of Huashan Hospital, Fudan University. The approval number of ethics committee was No. 2015-422. The written informed consents were provided by the patients before enrollment.

Data and Sample Collection

The demographics, immunoglobulin (Ig) subtypes, biochemical indexes levels, bone lesion status, renal impairment status, and chromosomal abnormalities were collected from electronic medical records. The Durie-Salmon (DS) stage was assessed based on hemoglobin (Hb) level, serum calcium level, bone X-ray result, and low M-component production rate according to the criteria of ISS for MM. The BM samples of patients with MM were collected before initial treatment, and the BM samples of healthy donors were collected on the enrollment. After collection, the BM samples were processed with gradient density centrifugation to isolate BM mononuclear cells. Then, the plasma cells were purified from BM mononuclear cells with the
use of CD138-coated magnetic beads (Miltenyi Biotec; Catalog No. 130-051-301), and the purified plasma cells were stored in liquid nitrogen for further detection.

**Reverse Transcription Quantitative Polymerase Chain Reaction**

Reverse transcription quantitative polymerase chain reaction (qPCR) was performed to detect the relative expression of Inc-PVT1 and c-Myc in plasma cells. After the extraction of total RNA by PureZOL RNA isolation reagent (Bio-Rad; Catalog No. 7326880), RNA was converted to complementary DNA (cDNA) using iScript cDNA Synthesis Kit (Bio-Rad; Catalog No. 1708890). The cDNA product was subsequently subjected to qPCR with KOD SYBR qPCR Mix (Toyobo; Catalog No.QKD-201 T). The polymerase chain reaction amplification was performed as follows: 95 °C for 5 minutes, followed by 40 cycles of amplification (95 °C for 5 seconds, 61 °C for 15 seconds). The qPCR result was calculated by the $2^{-\Delta\Delta C_t}$ method with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as the reference gene. After that, the $2^{-\Delta\Delta C_t}$ method was applied for calculating the expressions of candidate RNAs as follows: $\Delta C_t$ (test) = $C_t$ (target, test) − $C_t$ (reference, test), $\Delta C_t$ (calibrator) = $C_t$ (target, calibrator) − $C_t$ (reference, calibrator), $\Delta\Delta C_t$ = $\Delta C_t$ (test) − $\Delta C_t$ (calibrator), then the relative expression of target gene was calculated as $2^{-\Delta\Delta C_t}$. The primers were as follows: Inc-PVT1 forward primer: CGAGCTCGGAGCAAAGATGTT, reverse primer: CCGTGTCCTCCAACAGTGCA; c-Myc forward primer: CAGCTGCTTAGACGCTGGATT, reverse primer: GTAGAAATACGGCTGCACCGA; GAPDH; forward primer: TGACCACAGTCATGCCATCAC, reverse primer: GCCTGCTTCACCACCTTCTTG.

**Treatment and Clinical Response Assessment**

After the patients were admitted in our hospital, appropriate treatments (such as bortezomib/dexamethasone and melphalan/prednisone/bortezomib) were given to them according to the clinical conditions, and their clinical response was assessed after treatment for 2 cycles in accordance with National Comprehensive Cancer Network clinical practice guidelines in oncology: MM (2015.V4) as follows: (1) complete response (CR) was defined as negative immuno fixation on the serum and urine and disappearance of any soft tissue plasmacytomas and <5% plasma cells in BM; (2) very good partial response (VGPR) was defined as serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level <100 mg per 24 hours; (3) partial response (PR) was defined as ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to <200 mg per 24 hours; and (4) overall response rate (ORR) was defined as CR + VGPR + PR.

**Follow-Up**

All patients were regularly followed up to June 30, 2019, and the median follow-up duration was 21.5 months. Progression-free survival (PFS) was calculated from the date of initial treatment to the date of disease progression or death. Overall survival (OS) was calculated from the date of initial treatment to the date of death. Patients not known to have disease progressed or have died at the last follow-up date were censored on the date of last visit or the date last known to be alive.

**Statistical Analysis**

Statistical analyses were performed using SPSS 24.0 (IBM). Figures were plotted using GraphPad Prism 7.00 (GraphPad Software). Descriptive analyses of continuous variables were expressed as mean ± standard deviation or median (interquartile range). Descriptive analyses of categorical variables were displayed as count and percentage. Comparison of Inc-PVT1 relative expression between healthy donors and patients with MM was determined by Wilcoxon rank-sum test. Comparison of high and low expressions of Inc-PVT1 with biochemical index was determined by Wilcoxon rank-sum test. Correlation of high and low expressions of Inc-PVT1 with ISS stage was analyzed by Wilcoxon rank-sum test. Correlation of high and low expressions of Inc-PVT1 with DS stage, chromosomal abnormality, CR, or ORR was determined by $\chi^2$ test. The ability of Inc-PVT1 in discriminating patients with MM from healthy donors was evaluated by receiver-operating characteristic (ROC) curve, the area under curve (AUC), and best cutoff point. Progression-free survival and OS were illuminated using Kaplan-Meier curves, and the difference of PFS and OS between 2 groups was determined by log-rank test. Factors predicting PFS or OS were analyzed by univariate and forward stepwise multivariate Cox proportional hazard regression model. A $P$ value <.05 was considered as significant.

**Results**

**Clinical Characteristics of Patients With MM**

The mean age was 55.0 ± 8.7 years old, and there were 46 (35.9%) females/82 (64.1%) males (Table 1). For Ig subtype, 70 (54.7%) patients presented with IgG, 35 (27.3%) patients presented with IgA, and 23 (18.0%) patients presented with others. The number of patients with bone lesion and renal impairment was 94 (73.7%) and 54 (42.2%), respectively. For DS stage, 12 (9.4%) patients and 116 (90.6%) patients were at stage II and at stage III, respectively. For ISS stage, 31 (24.2%) patients were at stage I, 33 (25.8%) patients were at stage II, and 64 (50.0%) patients were at stage III. As to biochemical indexes, the median value of Hb, calcium, serum creatinine, ALB, β2-MG, and lactate dehydrogenase (LDH) was 99.0 (83.0-113.8) g/L; 9.8 (8.7-11.1) mg/dL, 1.9 (1.4-2.3) mg/dL, 34.0 (29.0-38.0) g/L, 5.6 (3.1-8.8) mg/dL, and 216.6 (179.7-248.3) U/L, respectively. For chromosomal abnormalities, 12 (9.4%) patients were with t(4; 14), 6 (4.7%) patients were with t(14; 16), and 13 (10.2%) patients were with Del(17p). The detailed information is shown in Table 1.
The Expression of lnc-PVT1 and Its Performance in Distinguishing Patients With MM From Healthy Donors

The median value of lnc-PVT1 in patients with MM and healthy donors was 2.812 (1.840-4.492) and 1.026 (0.617-1.434), respectively (Figure 1A), and it was greatly higher in patients with MM than that in healthy donors ($P<.001$). The ROC curve showed that lnc-PVT1 distinguished patients with MM from healthy donors with AUC of 0.884 (95% CI: 0.829-0.940). The sensitivity and specificity were 75.0% and 93.3%, respectively, at the best cutoff point (that was a point with the largest sum of sensitivity and specificity; lnc-PVT1 = 1.864; Figure 1B). In addition, we also compared the lnc-PVT1 expression between primary patients with MM and patients with R/R MM, and we discovered lnc-PVT1 expression showed an increased trend in patients with R/R MM compared to patients with primary MM, but with no statistical significance ($P = .063$; Supplementary Figure 1).

Association of lnc-PVT1 Expression With Clinical Characteristics in Patients With MM

According to median value of lnc-PVT1 in patients with MM, all patients were divided into lnc-PVT1 high expression group and low expression group for the following analysis. For biochemical indexes, lnc-PVT1 expression positively correlated with $\beta$2-MG ($P = .011$), while no difference was found in the correlation of lnc-PVT1 with Hb ($P = .266$), calcium ($P = .387$), Scr ($P = .238$), ALB ($P = .247$), or LDH ($P = .952$; Table 2). For disease stage, no correlation was discovered for lnc-PVT1 expression with DS stage ($P = .544$; Figure 2A), while lnc-PVT1 high expression correlated with increased ISS stage ($P = .012$; Figure 2B). As to chromosomal abnormalities, high expression of lnc-PVT1 correlated with high Del(17p), $P = .041$ (Figure 3C), while there was no correlation of

Table 1. Clinical Characteristics.

| Items                        | Patients with MM (N = 128) |
|------------------------------|----------------------------|
| Age (years), mean ± SD       | 55.0 ± 8.7                 |
| Gender, no. (%)              |                            |
| Female                       | 46 (35.9)                  |
| Male                         | 82 (64.1)                  |
| Immunoglobulin subtype, no. (%) |                       |
| IgG                          | 70 (54.7)                  |
| IgA                          | 35 (27.3)                  |
| Others                       | 23 (18.0)                  |
| Bone lesion, no. (%)         |                            |
| No                           | 34 (26.6)                  |
| Yes                          | 94 (73.7)                  |
| Renal impairment, no. (%)    |                            |
| No                           | 74 (57.8)                  |
| Yes                          | 54 (42.2)                  |
| DS stage, no. (%)            |                            |
| II                           | 12 (9.4)                   |
| III                          | 116 (90.6)                 |
| ISS stage, no. (%)           |                            |
| I                            | 31 (24.2)                  |
| II                           | 33 (25.8)                  |
| III                          | 64 (50.0)                  |
| Biochemical indexes, median (IQR) |                      |
| Hb, g/L                      | 99.0 (83.0-113.8)          |
| Calcium, mg/dL               | 9.8 (8.7-11.1)             |
| Scr, mg/dL                   | 1.9 (1.4-2.3)              |
| ALB, g/L                     | 34.0 (29.0-38.0)           |
| $\beta$2-MG, mg/L            | 5.6 (3.1-8.8)              |
| LDH, U/L                     | 216.6 (179.7-248.3)        |
| Chromosomal abnormalities, no. (%) |                  |
| t(4; 14)                     | 12 (9.4)                   |
| t(14; 16)                    | 6 (4.7)                    |
| Del(17p)                     | 13 (10.2)                  |

Abbreviations: ALB, albumin; $\beta$2-MG, $\beta$-2-microglobulin; DS, Durie-Salmon; Hb, hemoglobin; IgA, immunoglobulin A; IgG, immunoglobulin G; IQR, interquartile range; ISS, International Staging System; LDH, lactate dehydrogenase; MM, multiple myeloma; Scr, serum creatinine; SD, standard deviation.

Figure 1. Expression of Lnc-PVT1 and ROC analysis of Lnc-PVT1. A, Comparison of Lnc-PVT1 expression between patients with MM and health donors. B, The performance of Lnc-PVT1 in distinguishing patients with MM from healthy donors. Lnc-PVT1 indicates long noncoding RNA plasmacytoma variant translocation 1; MM, multiple myeloma; ROC, receiver-operating characteristic.
lnc-PVT1 expression with t(4; 14), \(P = .225\) (Figure 3A) or t(14; 16), \(P = .208\) (Figure 3B). In addition, we assessed the correlation between lnc-PVT1 expression and c-Myc expression in patients with MM, and we found that lnc-PVT1 expression was positively correlated with c-Myc expression in patients with MM (\(P < .001, r = 0.361\); Supplementary Figure 2).

### Association of lnc-PVT1 Expression With Treatment Responses in Patients With MM

There were 36 (28.1%) patients who achieved CR and 94 (73.4%) patients who achieved ORR (Figure 4A). The percentage of patients achieved CR was lower in lnc-PVT1 high expression group than that in lnc-PVT1 low expression group (\(P = .018\); Figure 4B). In addition, the percentage of patients who achieved ORR was also reduced in lnc-PVT1 high expression group compared to lnc-PVT1 low expression group (\(P = .045\); Figure 4C).

### Association of lnc-PVT1 Expression With Survival Profiles in Patients With MM

Long noncoding RNA plasmacytoma variant translocation 1 high expression predicted poor PFS (\(P = .002\); Figure 5A) and worse OS (\(P = .012\); Figure 5B) in patients with MM.

### Table 2. Correlation of lnc-PVT1 With Biochemical Indexes.

| Items          | Lnc-PVT1 | P value |
|----------------|----------|---------|
|                | High     | Low     |       |
| Hb (g/L), median (IQR) | 94.0 (76.3-115.3) | 101.0 (86.3-117.8) | .266 |
| Calcium (mg/dL), median (IQR) | 10.0 (8.9-11.1) | 9.7 (8.4-12.3) | .387 |
| Scr (mg/dL), median (IQR) | 1.8 (1.6-2.6) | 1.9 (1.3-2.2) | .238 |
| ALB (g/L), median (IQR) | 32.0 (29.0-37.0) | 34.0 (29.0-39.0) | .247 |
| β2-MG (mg/L), median (IQR) | 6.4 (3.7-11.7) | 4.9 (2.5-7.3) | .011 |
| LDH (U/L), median (IQR) | 215.0 (181.4-251.6) | 216.6 (176.1-247.5) | .952 |

Abbreviations: ALB, albumin; β2-MG, β-2-microglobulin; Hb, hemoglobin; IQR, interquartile range; LDH, lactate dehydrogenase; lnc-PVT1, long noncoding RNA PVT1; Scr, serum creatinine.

*aComparison was analyzed by Wilcoxon rank-sum test.*
Univariate Cox regression analysis showed that lnc-PVT1 high expression (P = .003), bone lesion (P < .001), renal impairment (P = .001), ISS stage (P < .001), Scr (>2 mg/dL; P = .001), β2-MG (>5.5 mg/L; P < .001), LDH (>220 U/L; P = .025), and t(4; 14), P < .001, predicted poor PFS in patients with MM. Forward stepwise multivariate Cox regression analysis disclosed that lnc-PVT1 high expression could not independently predict PFS in patients with MM, while male (P = .008), β2-MG (>5.5 mg/L; P < .001), t(4; 14), P < .001, and Del(17p), P = .026, were independent factors for predicting worse PFS in patients with MM, which suggested that lnc-PVT1 might interact with β2-MG and Del(17p) to affect PFS in patients with MM (Table 3).

Prognostic Factors for OS in Patients With MM

Univariate Cox regression analysis showed that lnc-PVT1 high expression (P = .015), bone lesion (P = .008), renal impairment (P = .006), ISS stage (P < .001), Scr (>2 mg/dL; P = .021), β2-MG (>5.5 mg/L; P < .001), t(4; 14), P = .001, and t(14; 16), P = .021, predicted worse OS in patients with MM. Forward stepwise multivariate Cox regression analysis illustrated that lnc-PVT1 high expression was not an independent factor for predicting OS, while β2-MG (>5.5 mg/L; P < .001), t(4; 14), P = .005, and Del(17p) (P = .009) could independently predict decreased OS in patients with MM, which indicated that lnc-PVT1 might interact with β2-MG and Del(17p) to affect OS in patients with MM (Table 4).

Discussion

Accumulating evidence reveals that lnc-PVT1 is functionally linked to tumorigenesis of cancers. For example, one previous study discloses that lnc-PVT1 mediates miR-128-3p/Gremlin 1 axis and bone morphogenetic protein signaling pathway to increase cell growth in glioma.17 Meanwhile, lnc-PVT1 has been reported to suppress miR-195 to promote cell proliferation but decrease cell cycle arrest and apoptosis in osteosarcoma cells.18 Furthermore, another study reveals that lnc-PVT1 downregulates miR-16-5p to accelerate cell proliferation, invasion, and epithelial–mesenchymal transition in renal cell carcinoma.19 For hematologic malignancies, several comprehensive mechanisms between lnc-PVT1 and malignancies have been reported in continuance. On the one hand, lnc-PVT1 sponges multiple tumor suppressor microRNAs (miRNAs) in hematologic malignancies. For instance, lnc-PVT1 promotes MM cell proliferation and inhibits cell apoptosis via downregulating miR-203a.6 On the other hand, owing to the specific location of lnc-PVT1 on chromosome 8q24, chromosome 8q24 could cooperate with PML-RARα (an initiating factor for acute promyelocytic leukemia [APL] leukemogenesis) to induce
hematologic malignancies, including MM (above mentioned), the expression level and clinical implication of lnc-PVT1 in patients with MM are still unclear. Herein, we enrolled 128 patients with de novo MM and found that lnc-PVT1 was higher in patients with MM compared to healthy donors, and it could distinguish patients with MM from health donors.

More recently, lnc-PVT1 has been reported to be dysregulated and act as a convincing diagnostic biomarker in patients with a variety of cancers, including melanoma, pediatric malignancies, and liver cancer. However, limited evidences could be found about its role in patients with hematologic malignancies. One recent study reveals that the patients with APL presents with higher lnc-PVT1 expression compared with the controls. Although several evidences are regarding to the potential mechanism of lnc-PVT1 underlying additional genetic lesions, thereby blocking differentiation and accelerating the development of myeloid leukemia. Meanwhile, a previous study shows that knockdown of lnc-PVT1 contributes to Myc protein suppression to inhibit cell proliferation in APL. Thus lnc-PVT1 might affect the stability of several key proteins that are indispensable for cell growth in hematologic malignancies. On the basis of above-mentioned mechanisms, lnc-PVT1 might present with a high potential for clinical application in hematologic malignancies, including MM.

In recent years, a growing number of studies focus on the correlation of lnc-PVT1 with clinicopathological characteristics in patients with cancer, which display that lnc-PVT1 high expression is related to advanced clinicopathological characteristics in patients with solid tumor (such as lymph node metastasis and increased clinical stage in patients with melanoma metastasis and increased clinical stage in patients with hematologic malignancies). On the basis of above-mentioned mechanisms, lnc-PVT1 might affect the stability of several key proteins that are indispensable for cell growth in hematologic malignancies. Thus lnc-PVT1 might present with a high potential for clinical application in hematologic malignancies, including MM.

### Table 3. Factors Predicting PFS for Patients With MM.

| Items                      | Cox proportional hazard regression model | 95% CI               |
|----------------------------|-----------------------------------------|----------------------|
| Univariate Cox regression  |                                         |                      |
| Lnc-PVT1 high              | .003                                    | 2.134 1.291 3.526    |
| Age (>60 years)            | .930                                    | 0.976 0.572 1.667    |
| Male                      | .158                                    | 0.703 0.430 1.147    |
| Immunoglobulin subtype     |                                         |                      |
| IgG                       | .917                                    | 0.966 0.498 1.871    |
| Others                    | .764                                    | 1.090 0.621 1.911    |
| Bone lesion                | <.001                                   | 5.763 2.311 14.376   |
| Renal impairment           | .001                                    | 2.342 1.429 3.840    |
| DS stage                   | .420                                    | 0.737 0.351 1.547    |
| ISS stage                  | <.001                                   | 5.306 2.308 5.326    |
| ALB (>35 g/L)              | .085                                    | 0.537 0.264 1.088    |
| Calcium (>12 mg/dL)        | .090                                    | 1.922 0.904 4.087    |
| Scr (>2 mg/dL)             | .021                                    | 2.461 1.113 8.285    |
| LDH (>220 U/L)             | <.001                                   | 4.872 2.298 10.328   |
| t(4;14)                    | <.001                                   | 8.091 4.429 14.783   |
| t(14;16)                   | .265                                    | 1.784 0.645 4.937    |
| Del(17p)                   | .271                                    | 1.517 0.723 3.183    |

### Table 4. Factors Predicting OS for Patients With MM.

| Items                      | Cox proportional hazard regression model | 95% CI               |
|----------------------------|-----------------------------------------|----------------------|
| Univariate Cox regression  |                                         |                      |
| Lnc-PVT1 high              | .015                                    | 2.327 1.181 4.583    |
| Age (>60 years)            | .730                                    | 1.129 0.567 2.251    |
| Male                      | .420                                    | 1.328 0.666 2.645    |

Abbreviations: ALB, albumin; β2-MG, β-2-microglobulin; DS, Durie-Salmon; Hb, hemoglobin; HR, hazard ratio; IgA, immunoglobulin A; IgG, immunoglobulin G; ISS, International Staging System; LDH, lactate dehydrogenase; Lnc-PVT1, long noncoding RNA PVT1; MM, multiple myeloma; PFS, progression-free survival; Scr, serum creatinine.

Factors predicting PFS were analyzed by univariate and forward stepwise multivariate Cox proportional hazard regression model.

Factors predicting OS were analyzed by univariate and forward stepwise multivariate Cox proportional hazard regression model.
small cell lung cancer\textsuperscript{26}, invasion depth, advanced tumor-node-metastasis stage, and regional lymph nodes metastasis in patients with gastric cancer\textsuperscript{27}; as well as clinical stage and N-classification in patients with pancreatic ductal adenocarcinoma.\textsuperscript{28} For hematologic malignancies, just few previous studies have been performed. One previous study reveals that high level of Inc-PVT1 is associated with high-risk clinical features in patients with AML\textsuperscript{13}; another study discloses that Inc-PVT1 high expression is related to increased French-American-British subtypes stage in patients with APL.\textsuperscript{25} Whereas it is not yet clear for the clinical value of Inc-PVT1 in patients with MM. In the current study, we discovered that Inc-PVT1 high expression correlated with high β2-MG level, increased ISS stage, and raised Del (17p) in patients with MM. The possible explanations were as follows: firstly, Inc-PVT1 could sponge multiple miRNAs directly (including the inhibition of miR-203a and miR-214), which subsequently increased MM cell proliferation and reduced apoptosis, thereby devoting into advanced clinical features in patients with MM.\textsuperscript{6,29} Secondly, Inc-PVT1 might interact with c-Myc messenger RNA and also preserve c-Myc protein from phosphorylation at threonine 58 as well as subsequent degradation to accelerate disease progression, thereby contributing to worse clinical features in patients with MM.

Despite that the predictive value of Inc-PVT1 for poor prognosis has been determined in patients with various cancers (such as gastric cancer\textsuperscript{27} and pancreatic cancer\textsuperscript{28}) regarding to the influence of Inc-PVT1 on prognosis in hematologic malignancies, limited studies have been performed. Just one previous study discloses that high expression of Inc-PVT1 is associated with lower OS rate and leukemia-free survival in patients with AML, which suggests the potential of Inc-PVT1 to be a prognostic indicator for patients with AML.\textsuperscript{13} However, whether Inc-PVT1 also has a prognostic value in patients with MM is still unclear. Here, we discovered that Inc-PVT1 high expression predicted lower CR, ORR, poor PFS, and OS in patients with MM, which suggested that Inc-PVT1 expression predicted worse prognosis in patients with MM. The possible causes were as follows: firstly, Inc-PVT1 was related to aggravating clinical features, which contributed to poor prognosis in patients with MM (above mentioned).\textsuperscript{6,29} Secondly, Inc-PVT1 promoted drug resistance and also participated in autophagy-related pathways (including positive feedback loop of Inc-PVT1—forkhead M1), thereby resulting in worse prognosis in patients with MM\textsuperscript{30,31} However, we also found that Inc-PVT1 high expression was not an independent factor for predicting PFS and OS in patients with MM, which indicated that Inc-PVT1 might interact with multiple factors such as β2-MG and Del(17p) to result in short PFS and OS in patients with MM.

Despite of the interesting results in this study, some limitations still existed. Firstly, we just enrolled 128 patients with de novo MM, and the sample size in this study was relatively small, which might lead to poor statistical power. Thus, further study enrolling more patients with MM was necessary. Secondly, the detailed mechanism of Inc-PVT1 underlying MM pathogenesis was not investigated; hence further investigation was necessary. Thirdly, all patients with MM were patients with symptomatic MM, while the impact of Inc-PVT1 on clinical features and prognosis in patients with asymptomatic MM was still not explored. Finally, the change of Inc-PVT1 expression before treatment, after induction treatment, and after a certain time of consolidation treatment was not analyzed in this study, thus, further study was needed.

**Conclusion**

In conclusion, Inc-PVT1 distinguishes patients with MM from healthy donors, and it correlates with advanced clinical features as well as predicts worse prognosis of patients with MM, which indicates that Inc-PVT1 might be a potential biomarker for the supervision of disease progression and prognosis in patients with MM.

**Authors’ Note**

Pei Li and Xiyao Han contributed equally to this work. The ethical approval for this study was acquired from the Ethics Committee of Huashan Hospital, Fudan University. The approval number of ethics committee was No. 2015-422. The written informed consents were provided by the patients before enrollment.

**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.

**ORCID iD**

Pei Li \(\text{https://orcid.org/0000-0002-2870-7484}\)

**Supplemental Material**

Supplemental material for this article is available online.

**References**

1. Chavda SJ, Yong K. Multiple myeloma. Br J Hosp Med (Lond). 2017;78(2):C21-C27.
2. Palumbo A, Bringhen S, Ludwig H, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood. 2011;118(17):4519-4529.
3. Roussel M, Facon T, Moreau P, Harousseau JL, Attal M. Firstline treatment and maintenance in newly diagnosed multiple myeloma patients. Recent Results Cancer Res. 2011;183:189-206.
4. Lu W, Cao F, Wang S, Sheng X, Ma J. LncRNAs: the regulator of glucose and lipid metabolism in tumor cells. Front Oncol. 2019;9:1099.
5. Shen SN, Li K, Liu Y, Yang CL, He CY, Wang HR. Down-regulation of long noncoding RNA PVT1 inhibits esophageal carcinoma cell migration and invasion and promotes cell apoptosis via microRNA-145-mediated inhibition of FSCN1. Mol Oncol. 2019;13(12):2554-2573.
6. Yang M, Zhang L, Wang X, Zhou Y, Wu S. Down-regulation of miR-203a by IncRNA PVT1 in multiple myeloma promotes cell proliferation. Arch Med Sci. 2018;14(6):1333-1339.
7. Nagoshi H, Taki T, Hanamura I, et al. Frequent PVT1 rearrangement and novel chimeric genes PVT1-NBEA and PVT1-WWOX occur in multiple myeloma with 8q24 abnormality. Cancer Res. 2012;72(19):4954-4962.
8. Morlando M, Ballarino M and Fatica A. Long Non-Coding RNAs: New Players in Hematopoiesis and Leukemia. Front Med (Lausanne). 2015;2:23.
9. Graham M, Adams JM. Chromosome 8 breakpoint far 3' of the c-myc oncogene in a Burkitt’s lymphoma 2;8 variant translocation is equivalent to the murine pvt-1 locus. EMBO J. 1986;5(11):2845-2851.
10. Xu Y, Li Y, Jin J, et al. LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma. Mol Cancer. 2019;18(1):141.
11. Delgado MD, Leon J. Myc roles in hematopoiesis and leukemia. Genes Cancer. 2010;1(6):605-616.
12. Zheng C, Xiao Y, Li Y, He D. Knockdown of long non-coding RNA PVT1 inhibits the proliferation of Raji cells through cell cycle regulation. Oncol Lett. 2019;18(2):1225-1234.
13. El-Khazragy N, Elayat W, Matbouly S, et al. The prognostic significance of the long non-coding RNAs “CCAT1, PVT1” in t(8;21) associated Acute Myeloid Leukemia. Gene. 2019;707:172-177.
14. 2014 International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma [in Japanese]. Nihon Rinsho. 2016;74(suppl 5):264-268.
15. Durie BG and Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842-854.
16. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412-3420.
17. Fu C, Li D, Zhang X, Liu N, Chi G, Jin X. LncRNA PVT1 facilitates tumorigenesis and progression of glioma via regulation of MiR-128-3p/GREM1 axis and BMP signaling pathway. Neurotherapeutics. 2018;15(4):1139-1157.
18. Zhou Q, Chen F, Zhao J, et al. Long non-coding RNA PVT1 promotes osteosarcoma development by acting as a molecular sponge to regulate miR-195. Oncotarget. 2016;7(50):82620-82633.
19. Ren Y, Huang W, Weng G, Cui P, Liang H, Li Y. LncRNA PVT1 promotes proliferation, invasion and epithelial-mesenchymal transition of renal cell carcinoma cells through downregulation of miR-16-5p. Onco Targets Ther. 2019;12:2563-2575.
20. Jones L, Wei G, Sevcikova S, et al. Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia. J Exp Med. 2010;207(12):2581-2594.
21. Zeng C, Yu X, Lai J, Yang L, Chen S, Li Y. Overexpression of the long non-coding RNA PVT1 is correlated with leukemic cell proliferation in acute promyelocytic leukemia. J Hematol Oncol. 2015;8:126.
22. Chen X, Gao G, Liu S, et al. Long noncoding RNA PVT1 as a novel diagnostic biomarker and therapeutic target for melanoma. Biomed Res Int. 2017;2017:7038579.
23. Boloi A, Masanas M, Jimenez C, et al. Long non-coding RNA PVT1 as a prognostic and therapeutic target in pediatric cancer. Front Oncol. 2019;9:1173.
24. Zhang Y, Wen DY, Zhang R, et al. A preliminary investigation of PVT1 on the effect and mechanisms of hepatocellular carcinoma: evidence from clinical data, a meta-analysis of 840 cases, and in vivo validation. Cell Physiol Biochem. 2018;47(6):2216-2232.
25. IzadiFard M, Pashaiefar H, Yahgmaie M, et al. Expression analysis of PVT1, CCDC26, and CCAT1 long noncoding RNAs in acute myeloid leukemia patients. Genet Test Mol Biomarkers. 2018;22(10):593-598.
26. Huang C, Liu S, Wang H, Zhang Z, Yang Q, Gao F. LncRNA PVT1 overexpression is a poor prognostic biomarker and regulates migration and invasion in small cell lung cancer. Am J Transl Res. 2016;8(11):5025-5034.
27. Yuan CL, Li H, Zhu L, Liu Z, Zhou J, Shu Y. Aberrant expression of long noncoding RNA PVT1 and its diagnostic and prognostic significance in patients with gastric cancer. Neoplasma. 2016;63(3):442-449.
28. Huang C, Yu W, Wang Q, et al. Increased expression of the LncRNA PVT1 is associated with poor prognosis in pancreatic cancer patients. Minerva Med. 2015;106(3):143-149.
29. Misiewicz-Krzeminska I, Sarasquete ME, Quwaider D, et al. Restoration of microRNA-214 expression reduces growth of myeloma cells through positive regulation of P53 and inhibition of DNA replication. Haematologica. 2013;98(4):640-648.
30. Zhang XW, Bu P, Liu L, Zhang XZ, Li J. Overexpression of long non-coding RNA PVT1 in gastric cancer cells promotes the development of multidrug resistance. Biochem Biophys Res Commun. 2015;462(3):227-232.
31. Xu MD, Wang Y, Weng W, et al. A positive feedback loop of LncRNA-PVT1 and FOXM1 facilitates gastric cancer growth and invasion. Clin Cancer Res. 2017;23(8):2071-2080.